Download full-text PDF

Source
http://dx.doi.org/10.1038/d41586-023-01022-zDOI Listing

Publication Analysis

Top Keywords

africa-led group
4
group generates
4
generates lablab
4
lablab crop
4
crop genome
4
africa-led
1
generates
1
lablab
1
crop
1
genome
1

Similar Publications

Article Synopsis
  • An epidemic can persist in a community until it infects everyone, but it may eventually die out if the number of people able to get infected (susceptibles) decreases.
  • In small communities, there's a critical community size (CCS), which is the minimum number of susceptibles needed to keep an infection alive after an outbreak; below this point, the infection is likely to extinguish without external reintroduction.
  • Research on HIV dynamics shows that using a detailed computation method can help determine the CCS, suggesting that with effective control strategies, locations like Madagascar could see a temporary eradication of HIV within about 7.36 years, barring any outside infections.
View Article and Find Full Text PDF

A decade of antiretroviral therapy in Uganda: what are the emerging causes of death?

BMC Infect Dis

January 2019

Research Department, Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda.

Background: The roll out of antiretroviral therapy (ART) in Sub-Saharan Africa led to a decrease in mortality. Few studies have documented the causes of deaths among patients on long term antiretroviral therapy in Sub-Saharan Africa. Our objective was to describe the causes of death among patients on long term ART in Sub-Saharan Africa.

View Article and Find Full Text PDF

Neisseria meningitidis is a major cause of bacterial meningitis worldwide especially in Africa. The capsular polysaccharide (CPS) is the main virulence factor and the target antigen for polysaccharide and conjugate vaccines. The high burden of serogroup A disease in the Meningitis Belt of sub-Saharan Africa led to the introduction of MenAfriVac, which has successfully reduced the number of cases of group A disease.

View Article and Find Full Text PDF

Willingness to pay for an Ebola vaccine during the 2014-2016 ebola outbreak in West Africa: Results from a U.S. National sample.

Hum Vaccin Immunother

July 2018

b Department of Behavioral Sciences and Health Education , Rollins School of Public Health, Emory University, Atlanta , GA , USA.

The 2014-2016 Ebola virus outbreak in West Africa led to advances in the development of vaccines against Ebola. This study examined factors associated with willingness to pay for an Ebola vaccine among a U.S.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!